Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination

被引：1

作者：

Alidjinou, Enagnon Kazali ^{[1
]}

Demaret, Julie ^{[2
]}

Corroyer-Simovic, Benedicte ^{[3
]}

Vuotto, Fanny ^{[4
]}

Miczek, Sophie ^{[5
]}

Labreuche, Julien ^{[6
]}

Goffard, Anne ^{[7
]}

Trauet, Jacques ^{[2
]}

Lupau, Daniela ^{[2
]}

Dendooven, Arnaud ^{[2
]}

Huvent-Grelle, Dominique ^{[3
]}

Podvin, Juliette ^{[3
]}

Dreuil, Daniel ^{[3
]}

Faure, Karine ^{[4
]}

Deplanque, Dominique ^{[8
]}

Bocket, Laurence ^{[1
]}

Duhamel, Alain ^{[9
]}

Sobaszek, Annie ^{[10
]}

Hober, Didier

Hisbergues, Michael ^{[11
]}

Puisieux, Francois

Autran, Brigitte ^{[12
,13
]}

Yazdanpanah, Yazdan ^{[14
]}

Labalette, Myriam ^{[2
]}

Lefevre, Guillaume ^{[2
]}

机构：

[1] Univ Lille, CHU Lille, Lab Virol, Lille, France

[2] Univ Lille, Inst Immunol, CHU Lille, INFINITE Inst Translat Res Inflammat Inserm, Lille, France

[3] Univ Lille, Hop Geriatr Bateliers, CHU Lille, Pole Geriatr, Lille, France

[4] CHU Lille, Dept Malad Infectieuses, Lille, France

[5] CHU Lille, Mdecine & Sante Travail, Lille, France

[6] CHU Lille, Dept Biostat, Lille, France

[7] Univ Lille, Inst Pasteur Lille, CIIL U1019,CNRS,Inserm,CHU Lille, Ctr Infect & Immunite Lille Ctr Infect & Immunite, Lille, France

[8] Univ Lille, CIC Clin Invest Ctr 1403, Inserm, CHU Lille, F-59000 Lille, France

[9] Univ Lille, CHU Lille, EA 2694 Sante Publ Epidemiol & Qual Soins, Lille, Hauts De France, France

[10] Univ Lille, CHU Lille, Med & Sante Travail, ULR 4483, Lille, France

[11] Univ Lille, Ctr Ressources Biol, CHU Lille, Lille, France

[12] Sorbonne Univ, Paris, France

[13] Ctr Rech Immun Malad Infectieuses, UMR S Inserm, UPMC 1135, Paris, France

[14] Hop Bichat Claude Bernard, Infect Dis Dept, INSERM, IAME, Paris, France

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2023年 / 29卷 / 02期

关键词：

COVID-19; Neutralizing antibodies; Omicron; T cells;

D O I：

10.1016/j.cmi.2022.10.014

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: We investigated serum neutralizing activity against BA.1 and BA.2 Omicron sublineages and T cell response before and 3 months after administration of the booster vaccine in healthcare workers (HCWs). Methods: HCWs aged 18-65 years who were vaccinated and received booster doses of the BNT162b2 vaccine were included. AntieSARS coronavirus 2 IgG levels and cellular response (through interferon gamma ELISpot assay) were evaluated in all participants, and neutralizing antibodies against Delta, BA.1, and BA.2 were evaluated in participants with at least one follow-up visit 1 or 3 months after the administration of the booster dose. Results: Among 118 HCWs who received the booster dose, 102 and 84 participants attended the 1-month and 3-month visits, respectively. Before the booster vaccine dose, a low serum neutralizing activity against Delta, BA.1, and BA.2 was detectable in only 39/102 (38.2%), 8/102 (7.8%), and 12/102 (11.8%) participants, respectively. At 3 months, neutralizing antibodies against Delta, BA.1, and BA.2 were detected in 84/84 (100%), 79/84 (94%), and 77/84 (92%) participants, respectively. Geometric mean titres of neutralizing antibodies against BA.1 and BA.2 were 2.2-fold and 2.8-fold reduced compared with those for Delta. From 1 to 3 months after the administration of the booster dose, participants with a recent history of SARS coronavirus 2 infection (n = 21/84) had persistent levels of S1 reactive specific T cells and neutralizing antibodies against Delta and BA.2 and 2.2-fold increase in neutralizing antibodies against BA.1 (p 0.014). Conversely, neutralizing antibody titres against Delta (2.5-fold decrease, p < 0.0001), BA.1 (1.5-fold, p 0.02), and BA.2 (2-fold, p < 0.0001) declined from 1 to 3 months after the administration of the booster dose in individuals without any recent infection. Discussion: The booster vaccine dose provided significant and similar response against BA.1 and BA.2 Omicron sublineages; however, the immune response declined in the absence of recent infection. Enagnon Kazali Alidjinou, Clin Microbiol Infect 2023;29:258.e1-258.e4 (c) 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：258e1 / 258e4

页数：4

共 50 条

[1] Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
Evans, John P.
Zeng, Cong
Qu, Panke
Faraone, Julia
Zheng, Yi-Min
Carlin, Claire
Bednash, Joseph S.
Zhou, Tongqing
Lozanski, Gerard
Mallampalli, Rama
Saif, Linda J.
Oltz, Eugene M.
Mohler, Peter J.
Xu, Kai
Gumina, Richard J.
Liu, Shan-Lu
CELL HOST & MICROBE, 2022, 30 (08) : 1093 - +
[2] The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
Shuai, Huiping
Chan, Jasper Fuk-Woo
Hu, Bingjie
Chai, Yue
Yoon, Chaemin
Liu, Huan
Liu, Yuanchen
Shi, Jialu
Zhu, Tianrenzheng
Hu, Jing-Chu
Hu, Ye-fan
Hou, Yuxin
Huang, Xiner
Yuen, Terrence Tsz-Tai
Wang, Yang
Zhang, Jinjin
Xia, Yao
Chen, Lin-Lei
Cai, Jian-Piao
Zhang, Anna Jinxia
Yuan, Shuofeng
Zhou, Jie
Zhang, Bao-Zhong
Huang, Jian-Dong
Yuen, Kwok-Yung
To, Kelvin Kai-Wang
Chu, Hin
EBIOMEDICINE, 2023, 95
[3] Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination
Habermann, Elisa
Gieselmann, Lutz
Tober-Lau, Pinkus
Klotsche, Jens
Albach, Fredrik Nils
Ten Hagen, Alexander
Zernicke, Jan
Ahmadov, Elvin
de Silva, Amanthi Nadira Arumahandi
Frommert, Leonie Maria
Kurth, Florian
Sander, Leif Erik
Burmester, Gerd R.
Klein, Florian
Biesen, Robert
RMD OPEN, 2022, 8 (02):
[4] Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections
Qassim, Suelen H.
Chemaitelly, Hiam
Ayoub, Houssein H.
AlMukdad, Sawsan
Tang, Patrick
Hasan, Mohammad R.
Yassine, Hadi M.
Al-Khatib, Hebah A.
Smatti, Maria K.
Abdul-Rahim, Hanan F.
Nasrallah, Gheyath K.
Al-Kuwari, Mohamed Ghaith
Al-Khal, Abdullatif
Coyle, Peter
Kaleeckal, Anvar Hassan
Shaik, Riyazuddin Mohammad
Latif, Ali Nizar
Al-Kuwari, Einas
Jeremijenko, Andrew
Butt, Adeel A.
Bertollini, Roberto
Al-Romaihi, Hamad Eid
Al-Thani, Mohamed H.
Abu-Raddad, Laith J.
JOURNAL OF TRAVEL MEDICINE, 2022, 29 (06)
[5] SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
Stiasny, Karin
Weseslindtner, Lukas
Heinzel, Andreas
Camp, Jeremy V.
Oberbauer, Rainer
Reindl-Schwaighofer, Roman
TRANSPLANT INTERNATIONAL, 2022, 35
[6] Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus
Richter, Jan
Koptides, Dana
Tryfonos, Christina
Alexandrou, Denise
Christodoulou, Christina
MICROORGANISMS, 2022, 10 (09)
[7] Fatal cases after Omicron BA.1 and BA.2 infection: Results of an autopsy study
Maerkl, Bruno
Dintner, Sebastian
Schaller, Tina
Sipos, Eva
Kling, Elisabeth
Miller, Silvia
Lopez, Francisco Farfan
Grochowski, Przemyslaw
Reitsam, Nic
Waidhauser, Johanna
Hirschbuehl, Klaus
Spring, Oliver
Fuchs, Andre
Wibmer, Thomas
Boor, Peter
Beer, Martin
Wylezich, Claudia
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 128 : 51 - 57
[8] High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster
Guirakhoo, Farshad
Wang, Shixia
Wang, Chang Yi
Kuo, Hui-Kai
Peng, Wen-Jiun
Liu, Hope
Wang, Lixia
Johnson, Marina
Hunt, Adam
Hu, Mei Mei
Monath, Thomas P.
Rumyantsev, Alexander
Goldblatt, David
JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (08) : 1401 - 1406
[9] T cell epitopes are largely conserved in the SARS-CoV-2 Omicron subvariant (BA.1, BA.2, BA.3, and GKA)
Li, Hu
Chen, Zhiwei
Liu, Xiaoqing
Hu, Peng
JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (10) : 4591 - 4592
[10] Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data
Hirotsu, Yosuke
Maejima, Makoto
Shibusawa, Masahiro
Natori, Yume
Nagakubo, Yuki
Hosaka, Kazuhiro
Sueki, Hitomi
Mochizuki, Hitoshi
Tsutsui, Toshiharu
Kakizaki, Yumiko
Miyashita, Yoshihiro
Omata, Masao
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 486 - 491

← 1 2 3 4 5 →